Impact of rosuvastatin on atherosclerosis in people with HIV at moderate cardiovascular risk; a randomised, controlled trial.

Trevillyan, Janine M; Dart, Anthony; Paul, Eldho; Cavassini, Matthias; Fehr, Jan; Staehelin, Cornelia; Dewar, Elizabeth M; Hoy, Jennifer F; Calmy, Alexandra (2021). Impact of rosuvastatin on atherosclerosis in people with HIV at moderate cardiovascular risk; a randomised, controlled trial. AIDS, 35(4), pp. 619-624. Lippincott Williams & Wilkins 10.1097/QAD.0000000000002764

[img] Text
Impact_of_rosuvastatin_on_atherosclerosis_in.96531__1_.pdf - Accepted Version
Restricted to registered users only until 26 November 2021.
Available under License Publisher holds Copyright.

Download (246kB) | Request a copy

: People living with HIV-1 (PLHIV) are at increased risk for cardiovascular disease.

OBJECTIVE

This study aimed to determine if PLHIV would benefit from starting statins at a lower threshold than currently recommended in the general population.

DESIGN

A double-blind multicentre, randomised, placebo-controlled trial was performed.

METHODS

Participants (n = 88) with well controlled HIV, at moderate cardiovascular risk (Framingham score of 10-15%), and not recommended for statins were recruited from Australia and Switzerland. They were randomised 1:1 to rosuvastatin (n = 44) 20 mg daily, 10 mg if co-administered with ritonavir/cobicistat-boosted antiretroviral therapy, or placebo (n = 40) for 96 weeks. Assessments including fasting blood collection and carotid intima media thickness (CIMT) were performed at baseline, and weeks 48 and 96. The primary outcome was the change from baseline to week 96 in CIMT. (clinicaltrials.gov:NCT01813357) RESULTS:: Participants were predominantly male (82 (97·6%)); mean age 54 years (SD 6·0). At 96 weeks there was no difference in the progression of CIMT between the rosuvastatin (mean 0·004 mm, SE 0·0036) and placebo (0·0062 mm, SE 0·0039) arms (p value = 0·684), leading to no difference in CIMT levels between groups at week 96 (rosuvastatin arm, 0·7232 mm (SE 0·030); placebo arm 0·7785 mm (SE 0·032), p = 0·075).Adverse events were common (n = 146) and predominantly in the rosuvastatin arm (108 [73·9%]). Participants on rosuvastatin were more likely to cease study medication due to an adverse event (7 [15.9%] vs 2 [5·0%], p = 0.011).

CONCLUSIONS

In PLHIV statins prescribed at a lower threshold than guidelines did not lead to improvements in CIMT but was associated with significant adverse events.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Staehelin, Cornelia

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0269-9370

Publisher:

Lippincott Williams & Wilkins

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

30 Dec 2020 13:36

Last Modified:

24 Feb 2021 09:53

Publisher DOI:

10.1097/QAD.0000000000002764

PubMed ID:

33252480

BORIS DOI:

10.48350/149119

URI:

https://boris.unibe.ch/id/eprint/149119

Actions (login required)

Edit item Edit item
Provide Feedback